Alterity Therapeutics (ATHE) Cash from Financing Activities (2016 - 2019)

Alterity Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $166760.3 for Q4 2019.

• On a quarterly basis, Cash from Financing Activities rose 62.62% year-over-year to $166760.3 in Q4 2019; TTM through Dec 2019 was $124416.7, a 97.8% decrease from a year earlier, with the FY2025 full-year figure at $25.4 million, up 318.28% from the prior year.
• Cash from Financing Activities rose to $166760.3 in Q4 2019 per ATHE's latest filing, from $102549.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $166760.3 in Q4 2019 and bottomed at -$115796.0 in Q4 2016.
• The 4-year median for Cash from Financing Activities is $36726.2 (2017), against an average of $31104.2.
• Across the five-year window, Cash from Financing Activities soared 452.44% in 2018 and jumped 62.62% in 2019, its largest moves.
• Year by year, Cash from Financing Activities stood at -$115796.0 in 2016, then surged by 74.87% to -$29096.6 in 2017, then surged by 452.44% to $102549.0 in 2018, then surged by 62.62% to $166760.3 in 2019.
• Per Business Quant, the three latest ATHE Cash from Financing Activities figures stand at $166760.3 (Q4 2019), $102549.0 (Q4 2018), and -$29096.6 (Q4 2017).